AR037627A1 - Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento - Google Patents
Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamentoInfo
- Publication number
- AR037627A1 AR037627A1 ARP020104674A ARP020104674A AR037627A1 AR 037627 A1 AR037627 A1 AR 037627A1 AR P020104674 A ARP020104674 A AR P020104674A AR P020104674 A ARP020104674 A AR P020104674A AR 037627 A1 AR037627 A1 AR 037627A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- headache
- weight
- manufacture
- oral administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una composición farmacéutica en forma de dosificación sólida para su administración oral, capaz de una rápida desintegración y dispersión dentro del tracto gastrointestinal, que comprende un compuesto que actúa como agonista del receptor 5HT1 o uno de sus derivados farmacéuticamente aceptable como ingrediente activo, en la que más de del 70% preferentemente más de 80%, más preferentemente más del 90% del ingrediente activo se disuelve en fluido gástrico simulado (SGF) durante cinco minutos en un aparato USPII de 10 rpm de velocidad de discriminación de las paletas. El uso de dicha composición farmacéutica para la fabricación de un medicamento para tratar estados asociados al dolor cefálico tal como dolor de cabeza en racimos, hemicránea paroxistica crónica, dolor de cabeza asociado a trastornos vasculares, dolor de cabeza asociado a substancias o a su supresión, dolor de cabeza por efecto rebote, dolor de cabeza de tensión y, en particular migrana. Uso de un componente básico de una pareja efervescente que comprende de 5 a 50% en peso, un desintegrante que comprende de 0,5 a 10% en peso, y una carga insoluble que comprende de alrededor de 30 a 99% en peso que incluye un agente de imbibición que él mismo comprende de alrededor de 1 a alrededor de 99% en peso, basado en el peso en seco de la forma de dosificación, para la preparación de la composición farmacéutica. Reivindicación 12: una composición según una cualquiera de las reivindicaciones 1 a 11, caracterizada por que el agonista del receptor 5HT1, es sumatriptan o uno de sus derivados farmacéuticos aceptable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0129117.8A GB0129117D0 (en) | 2001-12-05 | 2001-12-05 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AR037627A1 true AR037627A1 (es) | 2004-11-17 |
Family
ID=9927051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104674A AR037627A1 (es) | 2001-12-05 | 2002-12-03 | Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento |
Country Status (29)
Country | Link |
---|---|
US (1) | US20050032867A1 (es) |
EP (2) | EP1450770B1 (es) |
JP (1) | JP3699969B2 (es) |
KR (1) | KR100591237B1 (es) |
CN (1) | CN1289069C (es) |
AR (1) | AR037627A1 (es) |
AT (1) | ATE291900T1 (es) |
AU (1) | AU2002358602B2 (es) |
BR (1) | BR0214497A (es) |
CA (1) | CA2469019C (es) |
CO (1) | CO5580741A2 (es) |
DE (1) | DE60203537T2 (es) |
ES (1) | ES2236608T3 (es) |
FI (1) | FI20022128A (es) |
GB (1) | GB0129117D0 (es) |
HK (1) | HK1069111A1 (es) |
HU (1) | HU229313B1 (es) |
IL (1) | IL161997A (es) |
IS (1) | IS2481B (es) |
MX (1) | MXPA04005420A (es) |
MY (1) | MY129314A (es) |
NO (1) | NO329896B1 (es) |
NZ (1) | NZ532829A (es) |
PL (1) | PL194702B1 (es) |
PT (1) | PT1450770E (es) |
RU (1) | RU2285526C2 (es) |
TW (1) | TWI240638B (es) |
WO (1) | WO2003047552A2 (es) |
ZA (1) | ZA200403849B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
MXPA05010070A (es) | 2003-04-11 | 2005-11-23 | Pfizer | Combinacion farmaceutica. |
BRPI0410807A (pt) * | 2003-06-06 | 2006-06-27 | Glaxo Group Ltd | composição farmacêutica, e, método pata tratar um mamìfero sofrendo de ou susceptìvel a condições associadas com dor cefálica |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
EP1750677B1 (en) * | 2004-05-28 | 2017-02-01 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
US20060105039A1 (en) | 2004-10-21 | 2006-05-18 | Jin-Wang Lai | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
EP3263117A1 (en) | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
CN101431895A (zh) * | 2006-05-01 | 2009-05-13 | 卡普里康制药公司 | 新颖的曲坦制剂和制备它们的方法 |
WO2008039358A2 (en) * | 2006-09-30 | 2008-04-03 | Capricorn Pharma Inc. | Resin-complex granulation for water-soluble drugs and associated methods |
RU2563623C2 (ru) | 2009-12-02 | 2015-09-20 | Апталис Фарма Лимитед | Микрокапсулы фексофенадина и содержащие их композиции |
US11364225B2 (en) | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5468504A (en) * | 1990-12-21 | 1995-11-21 | Laboratoires Glaxo S.A. | Effervescent pharmaceutical compositions |
GB9027827D0 (en) * | 1990-12-21 | 1991-02-13 | Glaxo Laboratoires | Pharmaceutical compositions |
GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
US5460972A (en) * | 1991-04-08 | 1995-10-24 | Research Foundation Of The State University Of New York | Ionized magnesium2+ concentrations in biological samples |
US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
WO1999043306A1 (en) * | 1998-02-26 | 1999-09-02 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
US6350470B1 (en) * | 1998-04-29 | 2002-02-26 | Cima Labs Inc. | Effervescent drug delivery system for oral administration |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
CA2392810A1 (en) * | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
KR20010107754A (ko) * | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
US20030008005A1 (en) * | 2001-07-05 | 2003-01-09 | R.T. Alamo Ventures, Inc. | Sublingual administration of dihydroergotamine for the treatment of migraine |
-
2001
- 2001-12-05 GB GBGB0129117.8A patent/GB0129117D0/en not_active Ceased
-
2002
- 2002-12-03 FI FI20022128A patent/FI20022128A/fi not_active Application Discontinuation
- 2002-12-03 TW TW091134979A patent/TWI240638B/zh not_active IP Right Cessation
- 2002-12-03 MY MYPI20024534A patent/MY129314A/en unknown
- 2002-12-03 AR ARP020104674A patent/AR037627A1/es unknown
- 2002-12-03 NO NO20025805A patent/NO329896B1/no not_active IP Right Cessation
- 2002-12-04 JP JP2003548808A patent/JP3699969B2/ja not_active Expired - Lifetime
- 2002-12-04 EP EP02792887A patent/EP1450770B1/en not_active Expired - Lifetime
- 2002-12-04 AU AU2002358602A patent/AU2002358602B2/en not_active Expired
- 2002-12-04 BR BR0214497-2A patent/BR0214497A/pt not_active Application Discontinuation
- 2002-12-04 HU HU0402178A patent/HU229313B1/hu unknown
- 2002-12-04 PL PL02370669A patent/PL194702B1/pl unknown
- 2002-12-04 PT PT02792887T patent/PT1450770E/pt unknown
- 2002-12-04 MX MXPA04005420A patent/MXPA04005420A/es active IP Right Grant
- 2002-12-04 CN CNB028244184A patent/CN1289069C/zh not_active Expired - Fee Related
- 2002-12-04 NZ NZ532829A patent/NZ532829A/en not_active IP Right Cessation
- 2002-12-04 CA CA002469019A patent/CA2469019C/en not_active Expired - Lifetime
- 2002-12-04 EP EP05075288A patent/EP1527773A1/en not_active Withdrawn
- 2002-12-04 RU RU2004120292/15A patent/RU2285526C2/ru not_active IP Right Cessation
- 2002-12-04 KR KR1020047008687A patent/KR100591237B1/ko active IP Right Grant
- 2002-12-04 AT AT02792887T patent/ATE291900T1/de active
- 2002-12-04 IL IL16199702A patent/IL161997A/xx active IP Right Grant
- 2002-12-04 DE DE60203537T patent/DE60203537T2/de not_active Expired - Lifetime
- 2002-12-04 ES ES02792887T patent/ES2236608T3/es not_active Expired - Lifetime
- 2002-12-04 WO PCT/EP2002/013715 patent/WO2003047552A2/en active IP Right Grant
- 2002-12-04 US US10/497,749 patent/US20050032867A1/en not_active Abandoned
-
2004
- 2004-05-19 ZA ZA2004/03849A patent/ZA200403849B/en unknown
- 2004-06-03 CO CO04052110A patent/CO5580741A2/es active IP Right Grant
- 2004-06-03 IS IS7293A patent/IS2481B/is unknown
-
2005
- 2005-02-28 HK HK05101699A patent/HK1069111A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR037627A1 (es) | Composicion farmaceutica en forma de dosificacion solida para su administracion oral y uso de dicha composicion farmaceutica y de un componente basico de una pareja efervescente para la fabricacion de un medicamento | |
JP2023134518A (ja) | 透過性増強された医薬組成物 | |
JP2023052143A (ja) | 送達増強エピネフリン組成物 | |
DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
ES2520990T3 (es) | Composiciones farmacéuticas que comprenden derivados de 2-oxo-1-pirrolidina | |
JPWO2002096406A1 (ja) | 医薬組成物 | |
IT1282352B1 (it) | Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per | |
NO20062004L (no) | Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav | |
CA2535803A1 (en) | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof | |
ES2282062T1 (es) | Composicion farmaceutica que contiene irbesartan. | |
JP4106232B2 (ja) | 医薬組成物 | |
PT2448561E (pt) | Composições farmacêuticas sólidas de dose fixa compreendendo irbesartan e amlodipina, sua preparação e seu aplicação terapêutica | |
JP2024507991A (ja) | 激越を処置するための方法及び組成物 | |
JP2005154437A (ja) | トラニラスト含有医薬組成物 | |
RU2010121919A (ru) | Диспиро 1, 2, 4-триоксоланы как противомалярийные средства | |
US20080242717A1 (en) | Methods for treating benign prostatic hyperplasia | |
BR112021010952A2 (pt) | Uso de extrato de cóculo-hirsuto para tratamento de dengue | |
JP4632687B2 (ja) | 点鼻剤 | |
ES2365409T3 (es) | Compuestos de dihidropiridina para enfermedades neurodegenerativas y demencia. | |
JP5054966B2 (ja) | 固形製剤 | |
CA3222959A1 (en) | Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists | |
KR20200131913A (ko) | 플루르비프로펜을 포함하는 약학적 조성물 | |
JP5468351B2 (ja) | 経口用医薬組成物 | |
ES2443968T3 (es) | Composiciones farmacéuticas de olmesartán | |
BR112020012157A2 (pt) | composição farmacêutica oral de um antagonista de nk-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |